Last reviewed · How we verify
Esomeprazole Magnesium Enteric-coated Tablets
Esomeprazole magnesium is a proton pump inhibitor that suppresses gastric acid secretion by irreversibly blocking the H+/K+-ATPase enzyme in gastric parietal cells.
Esomeprazole magnesium is a proton pump inhibitor that suppresses gastric acid secretion by irreversibly blocking the H+/K+-ATPase enzyme in gastric parietal cells. Used for Gastroesophageal reflux disease (GERD), Peptic ulcer disease, Zollinger-Ellison syndrome.
At a glance
| Generic name | Esomeprazole Magnesium Enteric-coated Tablets |
|---|---|
| Also known as | Nexium, Esomeprazole Magnesium |
| Sponsor | Fifth Affiliated Hospital, Sun Yat-Sen University |
| Drug class | Proton pump inhibitor (PPI) |
| Target | H+/K+-ATPase (proton pump) |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | Phase 3 |
Mechanism of action
Esomeprazole is the active S-enantiomer of omeprazole and works by inhibiting the final step of gastric acid production. The enteric coating allows the tablet to bypass the acidic stomach environment and dissolve in the small intestine, where the drug is absorbed and then transported to parietal cells to exert its acid-suppressing effect. This sustained acid suppression promotes healing of acid-related lesions and provides symptom relief.
Approved indications
- Gastroesophageal reflux disease (GERD)
- Peptic ulcer disease
- Zollinger-Ellison syndrome
- Prevention of NSAID-induced ulcers
Common side effects
- Headache
- Diarrhea
- Nausea
- Abdominal pain
- Constipation
Key clinical trials
- Drug Interaction Study on Linaprazan Glurate Capsules (PHASE1)
- Efficacy and Safety of Tegoprazan Versus Esomeprazole-containing Bismuth Quadruple Therapy for Eradication of Helicobacter Pylori (PHASE3)
- The Effect of PPI in Preventing Gastroesophageal Reflux Disease of Seafarers (PHASE3)
- Effect of Probiotics on Helicobacter Pylori Eradication (PHASE4)
- The Safety and Efficacy of the Enhanced Recovery After Surgery(ERAS)Applied on Cardiac Surgery With Cardiopulmonary Bypass (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: